Compare RNST & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | DYN |
|---|---|---|
| Founded | 1904 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 1995 | 2020 |
| Metric | RNST | DYN |
|---|---|---|
| Price | $39.86 | $18.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $43.00 | $37.00 |
| AVG Volume (30 Days) | 531.0K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.72 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $42.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.04 | $8.25 |
| 52 Week High | $42.11 | $25.00 |
| Indicator | RNST | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 50.52 |
| Support Level | $39.24 | $16.47 |
| Resistance Level | $40.60 | $19.65 |
| Average True Range (ATR) | 0.84 | 0.98 |
| MACD | -0.08 | -0.09 |
| Stochastic Oscillator | 40.12 | 43.54 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.